Plain-English translation of NCT07157774 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can reduce the risk of serious heart events — like heart attacks and strokes — in people who have high levels of a substance called lipoprotein(a) in their blood. Some participants have already had a heart attack or stroke, while others have risk factors that put them at higher risk for one. The medication is being compared to a placebo (a pill with no active ingredient) to see whether it actually works.
High lipoprotein(a) levels are linked to increased risk of heart attacks and strokes, and there are currently few treatment options specifically designed to address this problem. This trial exists to see whether this new treatment can help protect people from these serious cardiovascular events.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to take either the new medication or a placebo by mouth. You won't know which one you're receiving — that's part of the study design. You will have regular study visits where doctors will monitor your heart health, check your blood work, and track whether you experience any heart events. The study involves about 10,450 participants, so you'll be part of a large effort to understand whether this treatment works.
AI-generated summary from trial data · Oct 2, 2026 · Not medical advice
United States